Welcome to our dedicated page for Atai Beckley SEC filings (Ticker: ATAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AtaiBeckley Inc. filings document a clinical-stage biotechnology issuer with Nasdaq-listed common shares and psychiatry-focused investigational drug programs. The company’s regulatory record includes proxy and governance disclosures, shareholder voting matters, operating and financial results, clinical and regulatory updates, and risk-related information tied to development programs such as BPL-003, VLS-01, and EMP-01.
Material-event filings and registration-related documents also cover capital-structure activity, public offering agreements, resale registration matters, and acquisition-related share registration connected with Beckley Psytech. Historical filings under ATAI Life Sciences N.V. and Atai Beckley N.V. provide reference for the company’s corporate transition, financing activity, governance framework, and formal disclosure of business updates.
AtaiBeckley Inc. reported a wider loss for the three months ended March 31, 2026 as it continues to fund clinical-stage mental health programs. Total revenue was $0.95 million, mainly from Nualtis licensing and research services, compared with $1.56 million a year earlier.
Research and development expenses rose to $17.4 million and general and administrative expenses to $14.4 million, driving a net loss attributable to stockholders of $29.8 million, or $0.08 per share, versus $26.4 million and $0.15 per share in 2025. Cash and cash equivalents were $43.1 million and short-term securities $166.8 million as of March 31, 2026, and the company states this liquidity should fund operations for at least 12 months.
AtaiBeckley Inc. reported first quarter 2026 results showing continued investment in its mental health pipeline and a solid cash position. Revenue was $954 thousand, while research and development expenses rose to $17.4 million and general and administrative expenses to $14.4 million, reflecting higher clinical and personnel costs.
Net loss attributable to stockholders was $29.8 million, compared with $26.4 million a year earlier, as the company advances BPL-003 into a Phase 3 ReConnection program for treatment-resistant depression and continues Phase 2 development for VLS-01 and EMP-01. Cash, cash equivalents and short-term securities totaled $209.9 million as of March 31, 2026, and are expected to fund operations into 2029.
AtaiBeckley Inc. Chief Medical Officer Craig Kevin James executed a pre-planned option exercise-and-sale transaction involving company common stock. On the reported date, he sold 42,579 shares of common stock in an open-market sale at $5.00 per share and exercised stock options covering a total of 42,579 shares at exercise prices of $1.84 and $1.50 per share. The filing states that these option exercises and related sales were carried out under a Rule 10b5-1 trading plan adopted on December 19, 2025, indicating the trades were pre-arranged rather than timed discretionarily.
AtaiBeckley Inc. is asking stockholders to vote at its 2026 virtual annual meeting on June 4, 2026. The proxy seeks approval to elect three Class I directors — Sabrina Martucci Johnson, Amir Kalali, M.D., and Andrea Heslin Smiley — to terms ending at the 2029 annual meeting, and to ratify Deloitte & Touche LLP as independent auditor for 2026.
Holders of 366,916,896 common shares outstanding as of April 9, 2026 are entitled to one vote per share and may vote online, by telephone, or by mail. The company highlights its recent strategic combination of atai Life Sciences and Beckley Psytech and redomiciliation to Delaware, a classified nine‑member board, standard Nasdaq-based independence, and policies covering clawbacks, anti‑hedging, insider trading, and related‑party approvals.
The proxy details security ownership, including a 15.0% stake held by Apeiron Investment Group Ltd., board and committee composition, meeting procedures for the fully virtual format, auditor fees, and prior capital raises in 2025 via a public offering and PIPE financing that included significant Apeiron participation.
Morgan Stanley Smith Barney LLC Executive Financial Services filed a Rule 144 notice to sell 42,579 shares of Common Stock on 04/20/2026, described as resulting from an exercise of stock options and to be settled for cash. The filing lists the transaction as through an issuer-directed exercise.
The excerpt also discloses a prior 10b5-1 sale by Kevin James Craig of 100,000 shares on 03/20/2026 for proceeds of $355,480.00.
AtaiBeckley Inc. director and ten percent owner Christian Angermayer exercised stock options to acquire a total of 559,232 shares of common stock on April 8, 2026. The options were exercised at prices of $1.34, $1.64 and $1.88 per share.
Following these exercises, Angermayer holds 559,232 ATAI shares directly, in addition to substantial indirect holdings, including 1,799,302 shares held by Apeiron Presight Capital Fund II, L.P. and 53,412,414 shares held by Apeiron Investment Group Ltd. The filing shows option exercises only, with no reported open-market sales.
Atai Beckley N.V. (ATAI) reported a change to a director’s stock option. A previously granted option to purchase 40,400 common shares at an exercise price of $4.48 per share was amended on November 25, 2025 in connection with a consulting agreement.
Following the amendment, the reporting person now holds an option covering 10,000 common shares at the same exercise price of $4.48. Instead of vesting in 12 monthly installments beginning December 5, 2025, the option will vest in full on December 31, 2025, if the reporting person continues to provide service through that date.
Atai Beckley N.V. reported Q3 2025 results showing modest revenue but a larger loss driven by fair value changes and operating costs. Total revenue was $749 thousand, primarily from research and development services. Operating expenses reached $29.2 million (R&D $14.7 million, G&A $14.5 million), leading to a loss from operations of $28.4 million. Other expense was weighed by a $32.6 million net change in fair value of assets and liabilities. Net loss was $61.1 million (basic and diluted loss per share $0.28).
Year‑to‑date, revenue totaled $3.023 million and net loss was $115.3 million. Liquidity improved versus year‑end with $30.4 million in cash and cash equivalents, $84.2 million in securities carried at fair value, and $11.4 million in digital assets. Management states existing cash and short‑term securities as of September 30, 2025 will be sufficient to fund operations for at least the next 12 months from issuance. Financing activities included $118.2 million in equity offering proceeds, $21.5 million from pre‑funded warrants, and elimination of long‑term debt.
As of November 10, 2025, shares outstanding were 363,190,522. The company closed its strategic combination with Beckley Psytech on November 5, 2025 and changed its name to Atai Beckley N.V.